ClinicalTrials.gg
Active, not recruitingNCT02973529BIFSORBUpdated Jan 2, 2026

The Bioresorbable Implants for Scaffolding Obstructions in Randomized Bifurcations (BIFSORB) Study

An interventional study of Absorb and Desolve in Coronary Artery Disease, sponsored by Aarhus University Hospital Skejby. Active, not recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by Aarhus University Hospital Skejby · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby — none open to participants now, 4 under way, none of them phase 3. Coronary Artery Disease · Aarhus University Hospital Skejby.

Planned enrollment
12th of 15
120 · median 425
Started
2016
with 1 other
No phase
11 of 18
none open now
Registered
12th of 18
by date

Among the 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby, this one is the 12th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2016, is one of 11 with no phase, and was the 12th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

None of the 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby is open now. The open studies under Coronary Artery Disease, anywhere →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby as a file.
02

Study summary

Coronary artery disease is often treated by implantation of permanent metallic stents.Coronary stents are required in the early healing phase after balloon dilatation but constitute a lifelong foreign body. New bioresorbable stents have been developed and are believed to improve long-term safety. The purpose of this study is to compare the safety and vessel healing after treatment of simple bifurcation lesions with the CE-marked bioresorbable stents Absorb and Desolve.

Read the detailed description

BIFSORB is a prospective, randomized multicenter trial comparing 6-month healing outcome after treatment of simple coronary bifurcation lesions by Absorb or Desolve BRS. for treatment of coronary bifurcation lesions.

BRS are promising in treatment of coronary artery disease. The concept of bifurcation treatment using BRS is particular appealing as struts covering the side branch ostium may resorb over time.

The aim of this study is to compare the 6 months safety and vessel healing after treatment of coronary bifurcation lesions by the Desolve or Absorb BRS.

Hypothesis: Treatment of coronary bifurcation lesions using Absorb and Desolve bioresorbable stents is safe. Treatment of coronary bifurcation lesions by Desolve BRS is associated with a lower index of adverse vessel wall features (main vessel area stenosis, acquired malapposition, evaginations, late recoil, single end attached protruding struts, side branch ostial area stenosis) at 6 months compared to treatment with Absorb BRS.

Methods:

Prospective, open label, single blind, randomized, feasibility and safety pilot study with inclusion of 120 patients. Randomization 1:1 to Absorb or Desolve. Planned 6- and 24-month follow-up by OCT and follow-up for clinical endpoints until 10 years.

Eligible patients with a bifurcation lesion are treated by the provisional technique with mandatory jailing of the side branch and provisional opening of side branch ostium by the mini-kiss technique in case of severe pinching or TIMI-flow less than III. Proximal post-dilatation is mandatory. No dilatation beyond the expansion limits of the BRS.

The patients are assessed by optical coherence tomography (OCT) before, during and after implantation of the Absorb or Desolve BRS at baseline procedure and again at 6- and 24-month follow-up, or before if they are readmitted with a possible target lesion failure.

The operator is not blinded to pre-PCI OCT images that may be used for sizing and positioning of the scaffolds. Procedural OCT may be used to optimize scaffold implantation before performing final OCT.

Results are reported as clinical safety at 6 months (myocardial infarction, revascularization, death) and stent healing index by OCT including malapposition, stent coverage, side branch ostial area late loss, fracture and evaginations.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Percutaneous intervention (PCI)
  • Optical coherence tomography (OCT)
  • Bifurcation lesion
  • Bioresorbable stents (BRS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stable angina pectoris
  • Age > 18 years
  • Stabilized non-ST elevation myocardial infarction
  • Silent angina
  • De novo coronary bifurcation lesions at LAD/diagonal, CX/obtuse marginal, RCA-PDA/posterolateral branch
  • All Medina classes except Medina x.x.1
  • Diameter of side branch ≥ 2.5 mm
  • Signed

Exclusion criteria

Exclusion Criteria:

  • ST-elevation infarction within 48 hours
  • Expected survival \< 1 year
  • Severe heart failure (≥III)
  • S-creatinine > 120 µmol/L
  • Allergy to contrast media, aspirin, clopidogrel, ticagrelor, ticlopidine, everolimus or novolimus
  • Unable to cover main vessel lesion with one scaffold
  • Severe tortuosity
  • Severe calcification
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Absorb

    Randomization to implantation of Absorb BVS in bifurcation lesion

    Device: Absorb

  • Experimental
    Desolve

    Randomization to implantation of Desolve BRS in bifurcation lesion

    Device: Desolve

Interventions

  • DeviceAbsorb

    Randomization to implantation of Absorb BVS in bifurcation lesion

  • DeviceDesolve

    Randomization to implantation of Desolve BRS in bifurcation lesion

06

What researchers measure

Primary outcomes

  1. Number of participants with Clinical safety measured as: major procedural myocardial infarction, non-procedural target vessel myocardial infarction, target lesion failure, cardiac death.

    Clinical safety measured as: major procedural myocardial infarction, non-procedural target vessel myocardial infarction, target lesion failure, cardiac death.

    Time frame: 6 months

  2. Index of adverse vessel wall features

    Side branch ostial area late loss, strut fracture, uncovered non-side branch apposed stent struts, uncovered stent struts in front of side branch, uncovered stent struts on acquired or persistent malapposed struts, persistent malapposition, max neointimal thickness/area stenosis, cumulated extra stent lumen gain

    Time frame: 6 months

Secondary outcomes

  1. Optical coherence tomography endpoint: acute malapposition

    Time frame: Baseline

  2. Optical coherence tomography endpoint: acquired malapposition

    Time frame: 6 and 24 months

  3. Optical coherence tomography endpoint: persistent malapposition

    Time frame: 6 and 24 months

  4. Optical coherence tomography endpoint: Coverage of jailing struts

    Time frame: 6 and 24 months

  5. Optical coherence tomography endpoint: Extra stent lumen (including evaginations)

    Time frame: Baseline, 6 and 24 months

  6. Optical coherence tomography endpoint: Late stent recoil

    Time frame: 6 and 24 months

  7. Optical coherence tomography endpoint: stent fracture

    Time frame: Baseline, 6 and 24 months

  8. Optical coherence tomography endpoint: Single end attached protruding (floating) struts or neointimal tissue resembling struts

    Time frame: Baseline, 6 and 24 months

  9. Optical coherence tomography endpoint: Ostial strut loss

    Time frame: Baseline, 6 and 24 months

  10. Optical coherence tomography endpoint: Mean neointimal thickness

    Time frame: 6 and 24 months

  11. Optical coherence tomography endpoint: Stent strut coverage

    Time frame: 6 and 24 months

  12. Optical coherence tomography endpoint: Minimal luminal area in segmental analysis

    Time frame: Baseline, 6 and 24 months

  13. Optical coherence tomography endpoint: Minimal stent area in segmental analysis

    Time frame: Baseline, 6 and 24 months

  14. Optical coherence tomography endpoint: Minimum scaffold expansion area %

    Time frame: Baseline, 6 and 24 months

  15. Optical coherence tomography endpoint: Segmental area stenosis

    Time frame: Baseline, 6 and 24 months

  16. Optical coherence tomography endpoint: Healing above calcified plaque

    Time frame: 6 and 24 months

  17. Optical coherence tomography endpoint: Healing above lipid plaque

    Time frame: 6 and 24 months

  18. Optical coherence tomography endpoint: Acute thrombus on struts

    Time frame: Baseline

  19. Optical coherence tomography endpoint: Late thrombus on struts

    Time frame: 6 and 24 months

  20. Optical coherence tomography endpoint: Acute expansion

    Measured in segments with; 1) calcified plaque, 2) lipid plaque, 3) area after predilatation \< 30% of reference area, 4) stenosed segments (\>50% area stenosis) with no dissections after predilatation

    Time frame: Baseline

  21. Optical coherence tomography endpoint:Late recoil

    Measured in segments with; 1) calcified plaque, 2) lipid plaque, 3) area after predilatation \< 30% of reference area, 4) stenosed segments (\>50% area stenosis) with no dissections after predilatation

    Time frame: 6 and 24 months

  22. Angiographic endpoint: Ostial side branch area stenosis

    Time frame: Baseline, 6 and 24 months

  23. Angiographic endpoint: Ostial side branch acute gain after main vessel stenting

    Time frame: Baseline

  24. Angiographic endpoint: Ostial side branch late loss

    Time frame: 6 and 24 months

  25. Angiographic endpoint: Ostial distal main vessel area stenosis

    Time frame: Baseline, 6 and 24 months

  26. Angiographic endpoint: Ostial distal main vessel acute gain after main vessel stenting

    Time frame: Baseline

  27. Angiographic endpoint: Ostial distal main vessel late loss

    Time frame: 6 and 24 months

  28. Angiographic endpoint: Proximal main vessel area stenosis

    Time frame: Baseline, 6 and 24 months

  29. Angiographic endpoint: Proximal main vessel acute gain after main vessel stenting

    Time frame: Baseline

  30. Angiographic endpoint: Proximal main vessel late loss

    Time frame: 6 and 24 months

  31. Angiographic endpoint: Minimal luminal area of all segments

    Time frame: Baseline, 6 and 24 months

  32. Procedural endpoints: Procedure time

    From sheath insertion to closure device excluding treatment of other vessels

    Time frame: Baseline

  33. Procedural endpoints: Contrast use

    Time frame: Baseline

  34. Procedural endpoints: Fluoroscopy time

    Time frame: Baseline

Other outcomes

  1. Clinical endpoints: Myocardial infarction

    Time frame: 10 years

  2. Clinical endpoints: Target lesion failure

    Time frame: 10 years

  3. Clinical endpoints: Target lesion revascularization

    Time frame: 10 years

  4. Clinical endpoints: Stent thrombosis

    Time frame: 10 years

  5. Clinical endpoints: Cardiac death

    Time frame: 10 years

  6. Clinical endpoints: Non-Cardiac death

    Time frame: 10 years

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2016, a primary completion of Nov 2026 and a completion of Sep 2028. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2016
First posted
Nov 25, 2016
Start
Jan 2016
Primary completionEst.
Nov 2026
CompletionEst.
Sep 2028
Last update
Jan 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02973529
Lead sponsor
Aarhus University Hospital Skejby
Responsible party
Evald Hoej Christiansen (Principal investigator (MD, PhD), Aarhus University Hospital Skejby) — Principal investigator
First posted
Nov 25, 2016
Start date
Jan 2016
Primary completion
Nov 2026 (estimated)
Completion
Sep 2028 (estimated)
Last update
Jan 2, 2026

Study contacts

Evald H Christiansen, MD, PhD
principal investigator · Aarhus University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion